NovoCure Limited reports results for the quarter ended September 30 - Earnings Summary
NovoCure Limited reports results for the quarter ended September 30 - Earnings Summary
NovoCure Limited NVCR.OQ reported a quarterly adjusted loss of 9 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -33 cents. The mean expectation of seven analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -32 cents to -14 cents per share.
Revenue rose 15.7% to $193.40 million from a year ago; analysts expected $182.23 million.
NovoCure Limited's reported EPS for the quarter was a loss of 9 cents.
The company reported a quarterly loss of $10.44 million.
NovoCure Limited shares had fallen by 11.2% this quarter and gained 9.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for NovoCure Limited is $23.50, about 39.7% above its last closing price of $14.17
This summary was machine generated from LSEG data October 29 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2026 | -0.24 | -0.09 | Beat |
Jun. 30 2026 | -0.33 | -0.17 | Beat |
Mar. 31 2026 | -0.51 | -0.62 | Missed |
Dec. 31 2025 | -0.41 | -0.22 | Beat |
Recent news on NovoCure
See all newsBrief: Novocure’s PANOVA-3 Quality of Life, Pain Data Published in JAMA Network Open
US FDA declines to approve Novocure's lung cancer device
Brief: Novocure Provides FDA Update on Optune Mya Approval Application for Lung Cancer Brain Metastases
NovoCure Limited reports results for the quarter ended September 30 - Earnings Summary
Switzerland's Novocure Q3 revenue rises 16%, beats estimates